ArticlePaediatrics & child health2025
Striving for universal birth dose hepatitis B vaccination in Canada: data from Ontario make a compelling case.
Article in Paediatrics & child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2009, the World Health Organization called for global universal birth dose hepatitis B virus (HBV) vaccination; however, in Canada, five provinces still vaccinate adolescents. The National Advisory Committee on Immunization (NACI) recommends province-to-province assessment of local epidemiology and states that if there is a failure of the routine immunization program, as indicated by HBV infection occurring in infants and children awaiting vaccination, that changes should be made. It has now been shown in Ontario that children under the age of 12 who are born in Canada are acquiring HBV prior to adolescent vaccination. In regions where birth dose vaccination was implemented decades ago, there is a lower adult HBV prevalence. In addition, birth dose vaccination has been shown to be cost-effective in Canada. With these data, we strongly encourage NACI to provide a uniform Canadian recommendation, for provincial public health policymakers to move to universal birth dose vaccination, and for providers to offer universal vaccination accross Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.